Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma

A combination of atezolizumab with bevacizumab (AB) is the first regimen that has shown superiority compared to sorafenib and is now being used as the systemic treatment of choice for hepatocellular carcinoma (HCC) patients with Barcelona Liver Cancer Clinic stage C. However, a considerable number o...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ji Won, Jang, Jeong Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380709/
https://www.ncbi.nlm.nih.gov/pubmed/37511558
http://dx.doi.org/10.3390/ijms241411799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380709/
https://www.ncbi.nlm.nih.gov/pubmed/37511558
http://dx.doi.org/10.3390/ijms241411799

Ejemplares similares